title: Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less.
abstract: OBJECTIVE
  We report the estimates of 10-year prostate specific antigen (PSA) outcome following radical prostatectomy in patients with or without grade 4 or 5 disease in the needle biopsy or prostatectomy specimen stratified by the presenting PSA level.
  
  
  METHODS
  From 1989 to 2001, 2,254 patients treated with radical prostatectomy for clinically localized prostate cancer comprised the study cohort. PSA outcome was estimated using the actuarial method of Kaplan and Meier, and was stratified by the presenting PSA level and needle biopsy and prostatectomy Gleason score.
  
  
  RESULTS
  The 10-year estimates of PSA outcome declined significantly (p </=0.002) for patients with biopsy or prostatectomy Gleason score 6 or less as the presenting PSA level increased. This trend was observed for biopsy and prostatectomy Gleason score 7 or higher except for the PSA 4 or less group which did significantly worse (46% versus 62%, p = 0.03) compared to the PSA greater than 4 to 10 ng./ml. group. This finding may be explained by a low serum free testosterone level and the presence of a significantly higher proportion of prostatectomy Gleason score 8 to 10 disease (25% versus 16%, p = 0.03) in the PSA 4 or less versus greater than 4 to 10 ng./ml. group.
  
  
  CONCLUSIONS
  Patients with Gleason grade 4 or 5 disease in the radical prostatectomy specimen and a presenting PSA of 4 ng./ml. or less may be androgen deficient and have a significantly lower estimate of 10-year PSA outcome then expected based on the presenting PSA level.
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Anthony V
authors.initials: AV
authors.lastname: D'Amico
authors.forename: Ming-Hui
authors.initials: MH
authors.lastname: Chen
authors.forename: S Bruce
authors.initials: SB
authors.lastname: Malkowicz
authors.forename: Richard
authors.initials: R
authors.lastname: Whittington
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Renshaw
authors.forename: John E
authors.initials: JE
authors.lastname: Tomaszewski
authors.forename: Yelina
authors.initials: Y
authors.lastname: Samofalov
authors.forename: Alan
authors.initials: A
authors.lastname: Wein
authors.forename: Jerome P
authors.initials: JP
authors.lastname: Richie
mesh_terms: D000328:Adult; D000368:Aged; D000728:Androgens / Q000172:deficiency; D014408:Biomarkers, Tumor / Q000097:blood*; D001707:Biopsy, Needle; D015331:Cohort Studies; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*
chemical_list: D000728:Androgens; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen